Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Immunology Research
Cancer Immunology Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Table of Contents

Masters of Immunology

  • Masters of Immunology
    Innate Lymphoid Cells in Cancer
    Blandine Vallentin, Vincent Barlogis, Christelle Piperoglou, Sophie Cypowyj, Nicolas Zucchini, Matthieu Chéné, Florent Navarro, Catherine Farnarier, Eric Vivier and Frédéric Vély
    Cancer Immunol Res October 1 2015 3 (10) 1109-1114; DOI:10.1158/2326-6066.CIR-15-0222

Cancer Immunology at the Crossroads: Experimental Immunotherapies

  • Cancer Immunology at the Crossroads: Experimental Immunotherapies
    T-cell–based Immunotherapy: Adoptive Cell Transfer and Checkpoint Inhibition
    Roch Houot, Liora Michal Schultz, Aurélien Marabelle and Holbrook Kohrt
    Cancer Immunol Res October 1 2015 3 (10) 1115-1122; DOI:10.1158/2326-6066.CIR-15-0190

Cancer Immunology Miniatures

  • Cancer Immunology Miniatures | AuthorChoice
    Epithelial PD-L2 Expression Marks Barrett's Esophagus and Esophageal Adenocarcinoma
    Sarah Derks, Katie S. Nason, Xiaoyun Liao, Matthew D. Stachler, Kevin X. Liu, Jie Bin Liu, Ewa Sicinska, Michael S. Goldberg, Gordon J. Freeman, Scott J. Rodig, Jon M. Davison and Adam J. Bass
    Cancer Immunol Res October 1 2015 3 (10) 1123-1129; DOI:10.1158/2326-6066.CIR-15-0046

    Esophageal adenocarcinoma and Barrett's esophagus epithelial cells commonly express PD-L2 in the setting of a Th2-skewed chronic inflammatory environment. Additional tumors express PD-L1 in immune cells. Evaluation of PD-1 inhibition and PD-L2 as biomarkers is warranted.

Priority Brief

  • Priority Brief
    Follicle-Stimulating Hormone Receptor as a Target in the Redirected T-cell Therapy for Cancer
    Katarzyna Urbanska, Caitlin Stashwick, Mathilde Poussin and Daniel J. Powell Jr
    Cancer Immunol Res October 1 2015 3 (10) 1130-1137; DOI:10.1158/2326-6066.CIR-15-0047

    Ovarian cancers, and possibly tumor-associated vasculature, express follicle-stimulating hormone receptors (FSHRs), a potential target for antitumor immunity. T cells expressing anti-FSHR receptors killed tumors expressing the FSHR in vitro and reduced tumor growth in mouse models.

Research Articles

  • Research Articles
    Human Leukocyte Antigen (HLA) A*1101-Restricted Epstein-Barr Virus–Specific T-cell Receptor Gene Transfer to Target Nasopharyngeal Carcinoma
    Yong Zheng, Greg Parsonage, Xiaodong Zhuang, Lee R. Machado, Christine H. James, Asmaa Salman, Peter F. Searle, Edwin P. Hui, Anthony T.C. Chan and Steven P. Lee
    Cancer Immunol Res October 1 2015 3 (10) 1138-1147; DOI:10.1158/2326-6066.CIR-14-0203-T

    Nasopharyngeal carcinomas contain Epstein-Barr virus, with potentially immunogenic target epitopes. An HLA A*1101–restricted T-cell receptor (TCR) with specificity for LMP2 was cloned, could activate both CD4+ and CD8+ T cells, and inhibited tumor growth in a mouse model.

  • Research Articles
    Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti–PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells
    Benjamin Boyerinas, Caroline Jochems, Massimo Fantini, Christopher R. Heery, James L. Gulley, Kwong Yok Tsang and Jeffrey Schlom
    Cancer Immunol Res October 1 2015 3 (10) 1148-1157; DOI:10.1158/2326-6066.CIR-15-0059

    Inhibition of PD-L1 interferes with an immunosuppressive signal, thereby prolonging antitumor responses. A novel monoclonal antibody to PD-L1 also mediated antibody-dependent cell-mediated cytotoxicity (ADCC) of tumor cells, an additional mode of action for checkpoint inhibitors.

  • Research Articles
    Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma
    Marcella Callea, Laurence Albiges, Mamta Gupta, Su-Chun Cheng, Elizabeth M. Genega, André P. Fay, Jiaxi Song, Ingrid Carvo, Rupal S. Bhatt, Michael B. Atkins, F. Stephen Hodi, Toni K. Choueiri, David F. McDermott, Gordon J. Freeman and Sabina Signoretti
    Cancer Immunol Res October 1 2015 3 (10) 1158-1164; DOI:10.1158/2326-6066.CIR-15-0043

    Response to PD-L1 inhibition depends on its expression. Primary ccRCC tumors and their matching metastases were compared, and because PD-L1 was mostly in high nuclear-grade areas, these should be specifically selected for assessment to limit false negatives.

  • Research Articles | AuthorChoice
    Interleukin-6/STAT3 Pathway Signaling Drives an Inflammatory Phenotype in Group A Ependymoma
    Andrea M. Griesinger, Rebecca J. Josephson, Andrew M. Donson, Jean M. Mulcahy Levy, Vladimir Amani, Diane K. Birks, Lindsey M. Hoffman, Steffanie L. Furtek, Phillip Reigan, Michael H. Handler, Rajeev Vibhakar and Nicholas K. Foreman
    Cancer Immunol Res October 1 2015 3 (10) 1165-1174; DOI:10.1158/2326-6066.CIR-15-0061

    Subgroup A ependymoma are brain tumors with a poor prognosis. Tumors were found to be IL6/STAT3-dependent and infiltrated with polarized myeloid cells. Targeting this pathway to relieve immunosuppression could be an important approach for this tumor type.

  • Research Articles
    A Paracrine Role for IL6 in Prostate Cancer Patients: Lack of Production by Primary or Metastatic Tumor Cells
    Shu-Han Yu, Qizhi Zheng, David Esopi, Anne Macgregor-Das, Jun Luo, Emmanuel S. Antonarakis, Charles G. Drake, Robert Vessella, Colm Morrissey, Angelo M. De Marzo and Karen S. Sfanos
    Cancer Immunol Res October 1 2015 3 (10) 1175-1184; DOI:10.1158/2326-6066.CIR-15-0013

    The source of the IL6 production in prostate cancer was found to be tumor vasculature, not primary or metastatic tumor cells. This paracrine source may explain the low clinical activity of monoclonal antibodies targeting IL6 in prostate cancer.

  • Research Articles
    Radiographic Profiling of Immune-Related Adverse Events in Advanced Melanoma Patients Treated with Ipilimumab
    Sree Harsha Tirumani, Nikhil H. Ramaiya, Abhishek Keraliya, Nancy D. Bailey, Patrick A. Ott, F. Stephen Hodi and Mizuki Nishino
    Cancer Immunol Res October 1 2015 3 (10) 1185-1192; DOI:10.1158/2326-6066.CIR-15-0102

    As more melanoma patients are treated with CTLA-4 antibodies, immune-related adverse effects (irAEs) need elucidation. Radiographic imaging identified irAEs in 31% of patients, with colitis being most common. Most irAEs developed within 3 months of therapy.

Back to top
PreviousNext
Cancer Immunology Research: 3 (10)
October 2015
Volume 3, Issue 10
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

Jump to

  • Masters of Immunology
  • Cancer Immunology at the Crossroads: Experimental Immunotherapies
  • Cancer Immunology Miniatures
  • Priority Brief
  • Research Articles
Advertisement
  • Most Cited
  • Most Read
Loading
  • Activity of Anti-CTLA-4 Isotypes in Antitumor Responses
  • Masters of Immunology
  • Extending Reach of Checkpoint Blockade in Pancreatic Cancer
  • PD-L1 in Triple-Negative Breast Cancer
  • Case Report: RNA CAR T Cells
More...
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Cancer Immunology Essentials

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Immunology Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Immunology Research
eISSN: 2326-6074
ISSN: 2326-6066

Advertisement